Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302973 | 0.92 | MMP2 (0.32) | MMP2MMP3MMP9MMP14NQO1 | |
| SCHEMBL3159666 | 0.83 | CTNNB1 (0.39) | NQO1 | |
| SCHEMBL3589633 | 0.82 | NQO1 (0.50) | MMP2MMP3MMP9MMP14NQO1 | |
| SCHEMBL483029 | 0.79 | KDM4E (0.41) | — | |
| SCHEMBL2499531 | 0.79 | NQO1 (0.44) | NQO1PTPN1 | |
| SCHEMBL6008158 | 0.77 | — | — | |
| SCHEMBL919416 | 0.77 | KCNA3 (0.44) | — | |
| SCHEMBL919131 | 0.77 | KCNA3 (0.39) | — | |
| SCHEMBL6538593 | 0.76 | KCNA3 (0.48) | — | |
| SCHEMBL921536 | 0.76 | KCNA3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107721836-A | One kind synthesis 1,7 2（4 hydroxy phenyls）The method of the ketone of 1,4 diene of heptane 3 | 沈阳药科大学 | 2018-02-23 | — | — | CN | claimed |
| CN-100402152-C | Trimerisation of olefins using a catalyst comprising a source of chromium, molybdenum or tungsten and a ligand comprising at least one phosphorus, arsenic or antimony atom bound to at least one (hetero) hydrocarbyl group | BP CHEM INT LTD (GB) | 2008-07-16 | — | — | CN | claimed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | claimed |
| CN-1630554-A | Trimerisation of olefins using a catalyst containing chromium, molybdenum or tungsten and a ligand containing phosphorus, arsenic or antimony | BP CHEM INT LTD (GB) | 2005-06-22 | — | — | CN | claimed |
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| CN-1091768-C | Novel benzo-1, 3-dioxolyl-and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists | ABBOTT LAB CO (US) | 2002-10-02 | — | — | CN | claimed |
| EP-0888340-B1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-07-17 | — | — | EP | claimed |
| EP-0776324-B1 | ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-06-12 | — | — | EP | claimed |
| CN-1301264-A | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists | ABBOTT LAB (US) | 2001-06-27 | — | — | CN | claimed |
| EP-0292808-B1 | Substituted vinyl cephalosporins, process for their preparation and their use as medicines | BAYER AG (DE) | 1994-03-02 | — | — | EP | claimed |
| US-4988685-A | Cephalosporins derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | claimed |
| EP-0229381-B1 | METHIONINE-SUBSTITUTED 1,4-DIHYDROPYRIDINES, PROCESS FOR THE PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-05-30 | — | — | EP | claimed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | claimed |
| US-4840946-A | Benzazolythio-carbapenem antibiotics | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | claimed |
| US-4808622-A | ANTIHYPERTENSIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-28 | — | — | US | claimed |
| CN-88103202-A | Vinyl cephalosporin compound that replaces and preparation method thereof and as the application of medicine | — | 1988-12-21 | — | — | CN | claimed |
| EP-0292808-A2 | Substituted vinyl cephalosporins, process for their preparation and their use as medicines | BAYER AG (DE) | 1988-11-30 | — | — | EP | claimed |
| EP-0268963-A1 | Benzazolylthio-carbapenem antibiotics | BAYER AG (DE) | 1988-06-01 | — | — | EP | claimed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | MMP2 710/4885MMP3 944/4885MMP9 741/4885 |
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MMP2 1662/4885MMP3 2310/4885MMP9 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.